Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma.

Cancer Manag Res · 2015 · PMC4334173 · PMID 25709499

Europe PMC DOI

hedged sentence

0.2400

closest p · 4.8× alpha

0.2400

boldest claim

The sentences

did not reach statistical significanceP =0.24not close (p > 0.1)

The HR for PFS with axitinib titration when compared to placebo did not reach statistical significance (HR =0.85; 95% CI: 0.54–1.35; one-sided P =0.24).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.